The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

Worse still, if you'd only held Zoetis stock for the past one, or three, or five years, you would have lost money. Zoetis ...

Hypnotic Video of GIGANTIC US Aircraft Carriers in the Middle of the Sea 'Alligator Alcatraz' migrant detention camp in ...

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $1.62 per share. The animal health company posted revenue of $2.46 billion in the period, also topping ...

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance.

Trading volume stands at 1,715,669, with ZTS's price down by -0.4%, positioned at $145.2. RSI indicators show the stock to be may be approaching oversold. Earnings announcement expected in 4 days. 1 ...

In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...